Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies
Acquiring Company
EXICURE, INC.
Acquired Company
GPCR Therapeutics USA
SkokieCaliforniaOtherBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Exicure, Inc. (Nasdaq: XCUR) has announced the completion of its acquisition of GPCR Therapeutics USA Inc., a biotech company focusing on innovative treatments for autoimmune diseases and cancer. Along with the acquisition, Exicure also entered into a License and Collaboration Agreement with GPCR, aiming to advance the development and commercialization of GPCR’s technologies related to certain intellectual property and patents. This acquisition is anticipated to bolster Exicure’s capabilities in the field of cell and gene therapies, expanding its potential to address unmet medical needs across a diverse range of diseases.
Quick answer
EXICURE, INC. is acquiring GPCR Therapeutics USA, announced January 22, 2025. EXICURE, INC. is based in Skokie, Illinois, United States.
- How much did EXICURE, INC. pay for GPCR Therapeutics USA?
- The deal value was not disclosed.
- What does EXICURE, INC. do?
- Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
- Where are EXICURE, INC. and GPCR Therapeutics USA based?
- EXICURE, INC. is based in Skokie, Illinois, United States. GPCR Therapeutics USA is based in California, United States.
- Who are the decision-makers at EXICURE, INC?
- Fundz holds 2 contacts at EXICURE, INC. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- BioNTech completes acquisition of Biotheus to strengthen oncology strategy (February 4, 2025)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
- Novartis to acquire Anthos Therapeutics for up to $3.1 Billion, $3.1B (February 11, 2025)
- AbbVie completes acquisition of Nimble Therapeutics to expand its immunology pipeline (January 23, 2025)
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- Maravai LifeSciences completes acquisition of DNA and RNA Business from Officinae Bio to advance drug development capabilities (February 24, 2025)
Who to call at EXICURE, INC., and when
When EXICURE, INC. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day EXICURE, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at EXICURE, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at EXICURE, INC.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EXICURE, INC. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired GPCR Therapeutics USA?
GPCR Therapeutics USA was acquired by EXICURE, INC., based in Skokie. The deal was reported on January 22, 2025. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. EXICURE, INC. is publicly traded (XCUR) and operates in Other.
When did EXICURE, INC. acquire GPCR Therapeutics USA?
EXICURE, INC.'s acquisition of GPCR Therapeutics USA was reported on January 22, 2025. Exicure, Inc. (Nasdaq: XCUR) has announced the completion of its acquisition of GPCR Therapeutics USA Inc., a biotech company focusing on innovative treatments for autoimmune diseases and cancer. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does GPCR Therapeutics USA do?
GPCR Therapeutics USA Inc. is a biotech company focused on the development of innovative treatments for autoimmune diseases and cancer. It is privately held, operating in Biotechnology, and is based in California.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.